Physician profile
Thaeer E Sawa
NPI 1093109241
$3,449.98
in general payments reported to CMS, 2019-2025
12 companies · $785 in 2025
The $785 reported for 2025 was more than what 90% of General Practice providers received nationally (typical 2025 total: $105).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $714 · 2020: $443 · 2021: $281 · 2022: $493 · 2023: $384 · 2024: $349 · 2025: $785.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,519.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,518.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $796.13 | 2019-2025 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $755.67 | 2019-2025 | Breztri, Farxiga |
| Lilly USA, LLC | $747.92 | 2020-2025 | Zepbound, Jardiance |
| Amarin Pharma, INC. | $265.18 | 2019-2021 | |
| Otsuka America Pharmaceutical, INC. | $226.80 | 2023-2025 | Rexulti |
| Ardelyx, INC. | $124.89 | 2024 | Ibsrela |
| Phathom Pharmaceuticals, INC. | $122.76 | 2025 | Voquezna |
| E.R. Squibb & Sons, L.L.C. | $119.93 | 2025 | |
| Merck Sharp & Dohme LLC | $88.62 | 2024 | Verquvo |
| Amgen INC. | $71.40 | 2022-2023 | Evenity, Prolia |
| Exact Sciences Corporation | $66.00 | 2023-2025 | Cologuard Collection Kit |
| Pfizer INC. | $64.68 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thaeer Sawa listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.